Abstract
Summary
Product description
The present Competitive Intelligence Report about Anti-Infective Antibodies
provides a competitor evaluation in the field of recombinant monoclonal and
polyclonal antibodies and human plasma-derived immunoglobulins and
hyperimmunes for post-exposure prophylaxis and treatment of infectious
diseases as of November 2011. Purchase of the downloadable pdf report includes
a 6-month online access to the data of the report and any updates since the
publication date. Credentials to access the database will be sent by e-mail
and allow online work with the project data to print or export an individual
report.
The emergence of antibiotic resistant microorganisms, lethal viruses and the
threat of engineered microorganism have newly stimulated the interest in
recombinant antibodies for infectious diseases. Advances in understanding
pathogenetic mechanisms and new antibody technologies have further contributed
to a growing class of anti-infective antibodies. Apart from recombinant mono-
or polyclonal antibodies, human plasma-derived immunoglobulins have their
place in the treatment of immunedeficiencies and specific immunoglobulins
(hyperimmunes) are part of standard protocols in post-exposure prophylaxis of
a number of infectious diseases. Modern plasma-derived immunoglobulins are
characterized by improved purification procedures, more convenience (room
temperature stable, ready-to-use preparations, new stabilizers, higher
concentrated) and new developments.
The report includes a compilation of product portfolios and current active
projects in research and development of anti-infective antibodies and
immunoglobulins. In addition, the report lists company-specific R&D pipelines
product portfolios anti-infective antibodies, immunoglobulins and
hyperimmunes. Competitor projects are listed in a tabular format providing
information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information
about the pipeline of R&D projects for targets, diseases, technologies and
companies at low prices. The information is provided in a tabular format and
fully referenced.
Table of Contents
Recombinant Antibodies for Viral Diseases
- Respiratory Syncytial Virus (RSV)
- Human Immune Deficiency Virus (HIV)
- Hepatitis C Virus (HCV)
- Rabies Virus
- Influenza Virus
- Herpes Simplex Virus
- Hemorrhagic Fever Viruses
- Cytomegalovirus (CMV)
- Various Viruses
- Unspecified Virus, Broad Spectrum Antiviral Antibodies
Recombinant Antibodies for Bacterial Diseases
- Bacillus Anthracis
- Staphylococci
- Pseudomonas
- Streptococci
- Clostridium Difficile
- Clostridium Botulinum
- Various Bacteria
- Unspecified Bacteria, Broad Spectrum Antibacterial Antibodies
Recombinant Antibodies for Parasitic Diseases
Human Plasma-Derived Immunoglobulins
- Conventional Intravenous Immunoglobulins (IVIG)
- Enriched Immunoglobulins
- Injectable SC/IM Immunoglobulins
- Oral Immunoglobulins
Specific Immunoglobulins (Hyperimmunes)
- Varicella Zoster Immunoglobulins (VZIG)
- Tetanus Immunoglobulins
- Rabies Immunoglobulins
- Hepatitis B Immunoglobulins
- Hepatitis A Immunoglobulins
- Cytomegalovirus Immunoglobulins
- Vaccinia Immunoglobulins
- Various Immunoglobulins
Corporate Anti-Infective Antibody Portfolios and R&D Pipelines
Competitor Analysis: Anti-Infective Antibodies published by La Merie Publishing in November 21, 2011. This report consists of 160 Pages and the price starts from US $ 1086.
The contents of this page may be different from the latest version. Please contact us for details.
